Skip to main content

Targeting and exploiting B cell functions for treatment in cardiovascular disease

Objective

Cardiovascular disease (CVD) mortality and morbidity is predicted to increase in Europe and worldwide in the next decades due to aging and the rise of diabetes and obesity. The link between metabolic and inflammatory disease is getting stronger, raising hopes for novel therapeutic targets to be exploited clinically. Clinical evidence generated by the Academic partners of the Athero-B-Cell Consortium demonstrates that CVD is associated with pro- and anti-atherogenic B cell responses. We aim to use existing proteomic, transcriptomic and miRNA data generated from large-scale clinical studies in previous EU-funded collaborative efforts to decipher the pathways that favor pro- and anti-atherogenic B cell functions in order to unravel a new set of therapeutic targets and refine potential vaccine strategies for CVD. The selection and validation of targets will be made possible by substantial technological advance achieved by the participating SMEs that are world leaders in the field of bioinformatics, genetic modification including humanised mouse models, and 3rd generation antisense drugs with locked nucleic-acid (LNA) design that are in Phase II human trials. Academia-led innovation includes high-resolution methodologies such as CyTOF and ImageStream to interrogate available samples from clinical trials and the ability to validate the targets of interest in accredited models of CVD. The validation in vivo and in vitro of such targets will feed into the SME pipeline accelerating the process of drug discovery. The recent clinical success of 3rd generation antisense drugs underscores the advantage of the Athero-B-Cell approach: the seamless transition from validation tools to clinical applications. Harnessing protective or abating unwanted B cell responses has the potential to improve health, innovation and competitiveness of European SME and Academia, while shedding light on the pathogenesis of CVD, the world's biggest killer.

Field of science

  • /medical and health sciences/clinical medicine/endocrinology/diabetes
  • /social sciences/sociology/demography/mortality

Call for proposal

FP7-HEALTH-2013-INNOVATION-1
See other projects for this call

Funding Scheme

CP-FP - Small or medium-scale focused research project
Leaflet | Map data © OpenStreetMap contributors, Credit: EC-GISCO, © EuroGeographics for the administrative boundaries

Coordinator

THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD
Address
Wellington Square University Offices
OX1 2JD Oxford
United Kingdom
Activity type
Higher or Secondary Education Establishments
EU contribution
€ 1 035 840
Administrative Contact
Stephen Conway (Dr.)

Participants (10)

ROCHE INNOVATION CENTER COPENHAGEN AS
Denmark
EU contribution
€ 1 020 540
Address
Fremtidsvej 3
2970 Horsholm
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Henrik ørum (Dr.)
UNIVERSITE DE GENEVE
Switzerland
EU contribution
€ 531 000
Address
Rue Du General Dufour 24
1211 Geneve
Activity type
Higher or Secondary Education Establishments
Administrative Contact
François Mach (Prof.)
UNIVERSITA DEGLI STUDI DI GENOVA
Italy
EU contribution
€ 405 750
Address
Via Balbi 5
16126 Genova
Activity type
Higher or Secondary Education Establishments
Administrative Contact
Vincenzo Savarino (Prof.)
MAX IV Laboratory, Lund University
Sweden
EU contribution
€ 441 000
Address
Paradisgatan 5C
22100 Lund
Activity type
Higher or Secondary Education Establishments
Administrative Contact
Jacqueline Postma (Dr.)
UNIVERSITAIR MEDISCH CENTRUM UTRECHT
Netherlands
EU contribution
€ 441 000
Address
Heidelberglaan 100
3584 CX Utrecht
Activity type
Higher or Secondary Education Establishments
Administrative Contact
Karin Krol (Mrs.)
KAROLINSKA INSTITUTET
Sweden
EU contribution
€ 366 000
Address
Nobels Vag 5
17177 Stockholm
Activity type
Higher or Secondary Education Establishments
Administrative Contact
Caroline Hamilton (Mrs.)
University College London
United Kingdom
EU contribution
€ 526 498
Address
Gower Street
WC1E 6BT London
Activity type
Higher or Secondary Education Establishments
Administrative Contact
Kamila Kolasinska (Ms.)
BERING LIMITED
United Kingdom
EU contribution
€ 462 500
Address
Petersham Road 36
TW10 6UW Richmond
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Ignat Drozdov (Dr.)
GENOWAY
France
EU contribution
€ 492 050
Address
31 Rue Saint Jean De Dieu Technopark 2
69007 Lyon
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Angélique Heckmann (Dr.)
ALTA RICERCA E SVILUPPO IN BIOTECNOLOGIE SRLU
Italy
EU contribution
€ 170 000
Address
Via Fiorentina 151
53100 Siena
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Cristiana Tozzi (Dr.)